摘要:
Objective To investigate and analyze the effects of rosuvastatin on IL-6, GMP-140, BNP and cardiac function on the treatment of the elderly patients with acute coronary syndrome. Methods 66 elderly patients with acute coronary syndromes were selected from May 2015 to April 2017 in Tianjin Nankai Hospital. were randomly divided into control group and experimental group, 33 cases in each group. The control group were received routine oxygen inhalation and low molecular weight heparin, at this basis, and the experimental group were treated with rosuvastatin, 10 mg/d. All the patients were treated for 8 months. The heart function, interleukin -6, GMP-140, BNP and other clinical indexes before and after treatment in the two groups were compared and analyzed. Results After treatment, the level of LVEF in the experimental group was (60.12 ± 7.83)%, which was significantly higher than that in the control group (52.32 ± 6.67)%, the difference had statistically significant (P<0.05). The level of interleukin -6 in the control group was (32.20 ±4.23) ng/L, which was significantly higher than that in the experimental group (14.90 ± 4.23) ng/L, the difference had statistically significant (P<0.05). In addition, the levels of BNP and GMP-140 in the experimental group were (98.20 ± 37.65) ng/L, and (23.21 ± 5.43) μg / L, which were significantly lower than that in the control group, the difference had statistically significant (P<0.05). Conclusion Rosuvastatin was used in elderly patients with acute coronary syndrome, which can significantly alleviate the inflammatory reaction in the body, improve heart function, reduce serum GMP-140, BNP and interleukin -6 level.%目的 分析瑞舒伐他汀对老年急性冠脉综合征患者IL-6、GMP-140、BNP及心功能的影响.方法 选取2015年5月~2017年4月天津市南开医院收治的66例老年急性冠脉综合征患者为研究对象,随机分为对照组和试验组,每组33例.对照组进行常规吸氧、低分子肝素等治疗,试验组在此基础上进行瑞舒伐他汀治疗,口服,1天剂量为10 mg.试验组与对照组患者治疗时间均为8个月.比较分析试验组与对照组患者治疗前后的心功能及白细胞介素-6、GMP-140、BNP等临床指标.结果 治疗后,试验组LVEF水平为(60.12±7.83)%显著高于对照组LVEF水平(52.32±6.67)%,差异具有统计学意义(P<0.05).对照组白细胞介素-6水平为(32.20±4.23)ng/L显著高于试验组为(14.90±4.23)ng/L,差异具有统计学意义(P<0.05).试验组BNP与GMP-140水平分别为(98.20±37.65)ng/L与(23.21±5.43)μg/L显著低于对照组相关指标水平,差异具有统计学意义(P<0.05).结论 瑞舒伐他汀在老年急性冠脉综合征中的应用,能够显著缓解患者机体内炎症反应,改善心功能,降低患者GMP-140、BNP及白细胞介素-6水平.